menu
    • menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Asundexian

    Menu

    Asundexian

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Asundexian Phase III Study to Include Patients with Atrial Fibrillation Ineligible for Oral Anticoagulant ...

                            Details : BAY2433334 (asundexian) is as an oral direct, potent inhibitor of activated coagulation factor XI (FXIa), acts selectively on the coagulation cascade, thereby offering the potential to prevent events like stroke without a corresponding increase in bleedi...

                            Brand Name : BAY2433334

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 10, 2023

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Asundexian Phase III Study to Include Patients with Atrial Fibrillation Ineligible for Oral Anticoagulant ...

                            Details : BAY2433334 (asundexian) is an orally active coagulation factor Xia (FXIa) inhibitor, which is being evaluated for the treatment of patients (≥65 years of age) with atrial fibrillation (AF) at high risk for stroke or systemic embolism.

                            Brand Name : BAY2433334

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 06, 2023

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bayer Receives U.S. FDA Fast Track Designation for Asundexian Atrial Fibrillation Program

                            Details : BAY2433334 (asundexian) is as an oral direct, potent inhibitor of activated coagulation factor XI (FXIa), acts selectively on the coagulation cascade, thereby offering the potential to prevent events like stroke without a corresponding increase in bleedi...

                            Brand Name : BAY2433334

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 16, 2023

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor As...

                            Details : BAY2433334 (asundexian) is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention. It is being investigated for atrial fibrillation (AF) and non-cardioembolic ischemic stroke or high-risk transient i...

                            Brand Name : BAY2433334

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 08, 2023

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bayer Presents Positive Results From First Phase 2b Trial on Safety of Asundexian in Patients With Atrial Fibr...

                            Details : Data from PACIFIC-AF trial demonstrated lower observed rates of ISTH major and clinically relevant non-major bleeding for BAY2433334 (asundexian), a FXIa inhibitor, compared with apixaban in patients with atrial fibrillation at risk of stroke.

                            Brand Name : BAY2433334

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 03, 2022

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bayer Receives U.S. FDA Fast Track Designation for Asundexian Stroke Program

                            Details : BAY2433334 (asundexian), is an oral inhibitor of Factor XIa, as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke, is currently in Phase II clinical trials in all three indications either as a standalone ...

                            Brand Name : BAY2433334

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 10, 2022

                            Lead Product(s) : Asundexian

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth